Impact of smoking history on the efficacy of gefitinib in patients with non-small cell lung cancer harboring activating epidermal growth factor receptor mutations
S Igawa, J Sasaki, S Otani, M Ishihara, A Takakura… - Oncology, 2015 - karger.com
Background: Gefitinib treatment has come to be recognized as the standard therapy for
patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor …
patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor …
Epidermal growth factor receptor mutations in patients with non–small cell lung cancer
BE Johnson, PA Jänne - Cancer research, 2005 - AACR
A year has passed since mutations of the tyrosine kinase domain of the epidermal growth
factor receptor (EGFR) were discovered in patients with non–small cell lung cancer …
factor receptor (EGFR) were discovered in patients with non–small cell lung cancer …
Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
M Takeda, I Okamoto, J Tsurutani, N Oiso… - Japanese journal of …, 2012 - academic.oup.com
Objective Somatic mutations in the epidermal growth factor receptor gene are associated
with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors …
with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors …
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
C Gridelli, F De Marinis, M Di Maio, D Cortinovis… - Lung Cancer, 2011 - Elsevier
Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …
[HTML][HTML] A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama …
H Yoshioka, K Hotta, K Kiura, N Takigawa… - Journal of Thoracic …, 2010 - Elsevier
Backgrounds Efficacy of gefitinib therapy strongly depends on epidermal growth factor
receptor (EGFR)-mutation status in Asian patients with non-small cell lung cancer. Recently …
receptor (EGFR)-mutation status in Asian patients with non-small cell lung cancer. Recently …
Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients
C Wang, K Zhao, S Hu, W Dong, Y Gong, M Li, C Xie - Lung Cancer, 2022 - Elsevier
Background The purpose of this study was to investigate the outcomes of gefitinib and
erlotinib in patients with non-small cell lung cancer (NSCLC) with uncommon epidermal …
erlotinib in patients with non-small cell lung cancer (NSCLC) with uncommon epidermal …
Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L
Y Urata, N Katakami, S Morita, R Kaji… - Journal of Clinical …, 2016 - ascopubs.org
Purpose The epidermal growth factor receptor (EGFR) tyrosine kinase has been an
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
Efficacy of gefitinib for non‐adenocarcinoma non‐small‐cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of …
T Shukuya, T Takahashi, R Kaira, A Ono… - Cancer …, 2011 - Wiley Online Library
The efficacy of gefitinib for patients with non‐adenocarcinoma non‐small‐cell lung cancer
(NSCLC) harboring epidermal growth factor receptor (EGFR) mutations is unclear, because …
(NSCLC) harboring epidermal growth factor receptor (EGFR) mutations is unclear, because …
Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations
Purpose To evaluate the relationship between the epidermal growth factor receptor (EGFR)
mutation status and the effectiveness of gefitinib monotherapy or chemotherapy in patients …
mutation status and the effectiveness of gefitinib monotherapy or chemotherapy in patients …
[HTML][HTML] Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer
YY Shao, CC Lin, CH Yang - Discovery Medicine, 2010 - discoverymedicine.com
Tyrosine kinase inhibitors of the epidermal growth factor receptor, gefitinib and erlotinib,
have changed the treatment paradigm of advanced non-small cell lung cancer (NSCLC) …
have changed the treatment paradigm of advanced non-small cell lung cancer (NSCLC) …